Wolverine Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Wolverine Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,705	Closed	-$41.4K	–	1512
2019 Q3	$46K	Hold	1,705	–	–	﹤0.01%	1226
2019 Q2	$56K	Hold	1,705	–	–	﹤0.01%	1191
2019 Q1	$59K	Hold	1,705	–	–	﹤0.01%	1168
2018 Q4	$56K	Hold	1,705	–	–	﹤0.01%	1407
2018 Q3	$85K	Buy	+1,705	New	+$84.2K	﹤0.01%	1303
2015 Q2	–	Sell	-1,000	Closed	-$14.2K	–	2005
2015 Q1	$12K	Sell	1,000 -43,200	-98%	-$408K	﹤0.01%	1525
2014 Q4	$366K	Buy	44,200 +12,803	+41%	+$108K	0.01%	751
2014 Q3	$272K	Hold	31,397	–	–	0.01%	919
2014 Q2	$343K	Sell	31,397 -12,000	-28%	-$107K	0.01%	727
2014 Q1	$387K	Buy	43,397 +18,500	+74%	+$170K	0.01%	665
2013 Q4	$187K	Sell	24,897 -33,300	-57%	-$233K	﹤0.01%	1192
2013 Q3	$426K	Sell	58,197 -74,703	-56%	-$502K	0.01%	827
2013 Q2	$854K	Buy	+132,900	New	+$783K	0.02%	529

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Wolverine Asset Management's SUPN Position: Q4 2019 in Review

Wolverine Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2019, closing a stake of 1,705 shares — an estimated $41.4K sold.

Wolverine Asset Management first reported a position in SUPN in Q2 2013 and held it in 13 quarters. The position peaked at $854K in Q2 2013. 235 funds tracked by Wall St. Rank hold SUPN as of Q4 2019.

Wolverine Asset Management reported no remaining Supernus Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Wolverine Asset Management sold 1,705 Supernus Pharmaceuticals shares in Q4 2019, an estimated $41.4K.
Wolverine Asset Management first reported a position in Supernus Pharmaceuticals in Q2 2013 and held it in 13 quarters.
Wolverine Asset Management's Supernus Pharmaceuticals position peaked at $854K in Q2 2013.
235 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2019.

Based on Wolverine Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.